Keyphrases
Clinical Trials
100%
Hormone Therapy
100%
Women's Health Initiative
100%
Cardiovascular Biomarkers
100%
Conjugated Equine Estrogens
100%
Medroxyprogesterone Acetate
72%
Placebo
63%
Geometric Mean
54%
Estrogen Alone
45%
Low-density Lipoprotein Cholesterol (LDL-C)
36%
High-density Lipoprotein Cholesterol (HDL-C)
36%
Triglycerides
27%
Homeostasis Model Assessment of Insulin Resistance (HOMA-IR)
27%
Lipoproteins
27%
Trial Participants
18%
Estrogen
9%
Blood Samples
9%
Treatment Effect
9%
Cholesterol
9%
Cardiovascular Events
9%
Glucose-insulin System
9%
Regression Model
9%
Counsel
9%
Overall Effect
9%
Low-density Lipoprotein Cholesterol Level
9%
Menopausal Women
9%
Progestogens
9%
Bothersome Symptoms
9%
Restricted Maximum Likelihood
9%
Pharmacology, Toxicology and Pharmaceutical Science
Clinical Trial
100%
Biological Marker
100%
Endocrine Therapy
100%
Ethinylestradiol
100%
Conjugated Estrogen
100%
Medroxyprogesterone Acetate
47%
Placebo
41%
Low Density Lipoprotein Cholesterol
29%
Insulin Resistance
17%
High Density Lipoprotein Cholesterol
17%
Triacylglycerol
17%
Lipoprotein A
17%
Progestin
5%
Agricultural and Biological Sciences
Cardiovascular System
100%
Conjugated Estrogen
100%
Premarin
100%
Biological Marker
100%
Medroxyprogesterone Acetate
47%
Placebo
41%
Low Density Lipoprotein Cholesterol
29%
Insulin Resistance
17%
Triglyceride
17%
Lipoprotein
17%
High Density Lipoprotein Cholesterol
17%
Endpoints
5%
Progestin
5%
Restricted Maximum Likelihood
5%